▲ Peaking
Entertainment
DJ Khaled Opens Up About Dramatic 90-Pound Weight Loss Journey After Troubling Incident
DJ Khaled's 90-pound weight loss, tied to a troubling incident, is now the face of Novo's Wegovy marketing push.
Wegovy
68 trends tracked about this subject — the full history, oldest to newest below.
▲ Peaking
Entertainment
DJ Khaled reflects on using GLP-1s in 90-pound weight loss journey: ‘I needed help’
DJ Khaled publicly details a 75-to-90-pound weight loss aided by GLP-1 medication Wegovy, sparking wide entertainment-media coverage.
↓ Cooling
Health
Ozempic and Zepbound users face 6 rebound risks after stopping, doctor warns
Internal medicine physician Dr. Frank Dumont warns that stopping GLP-1 medications like Ozempic and Zepbound carries six rebound risks, including rapid weight regain, loss of cardiovascular protection, and worsening mental health.
◼ Archived
Business
FDA orders new warning labels on Ozempic, Wegovy over rare risk of permanent vision loss
Federal regulators mandate new vision loss warning labels across the widely used GLP-1 receptor agonist drug class.
◼ Archived
Business
FDA tells GLP-1 makers to warn of potential vision loss side effect
The FDA is requiring all GLP-1 drug makers to add warnings about a possible increased risk of NAION, a rare eye condition that can cause sudden and permanent vision loss.
◼ Archived
Business
US regulator orders makers of weight-loss drugs to carry blindness risk warning
The FDA is requiring all GLP-1 drug makers to add a warning about NAION, a rare eye condition that can cause sudden blindness, to their prescribing information.
◼ Archived
Health
An ‘Ozempic baby boom’? The GLP-1 pregnancy plot twist : Short Wave
A small Adelaide University sheep study found a single dose of semaglutide cut maternal cardiac output and fetal oxygen levels within two hours, raising new questions about GLP-1 drug safety during pregnancy.
◼ Archived
Business
Your job-based insurance cut GLP-1 coverage. Here are some options
Insurers are cutting coverage for GLP-1 weight-loss drugs, with coverage dropping from 57% to 53% between 2025 and 2026, while list prices range from $500 to over $1,000 monthly.
◼ Archived
Business
Novo Nordisk raises 2026 outlook as Q3 obesity sales jump 22%
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
Novo Nordisk Lifts Guidance as Rollout of Wegovy Weight-Loss Pill Continues
Novo Nordisk raises its 2026 outlook and shares surge as the Wegovy weight-loss pill rollout accelerates.
◼ Archived
Health
5 Menopause Research Updates That Could Shape Care
New research suggests a synergy between hormone therapy and GLP-1 weight-loss medications for women navigating menopause.
◼ Archived
Business
Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis
Novo's next-generation obesity drug CagriSema showed 25 percent weight loss in women in late-stage analysis.
◼ Archived
Health
15% Of Americans Have Taken A GLP-1, And Dermatologists Now Have A Timeline For When The Hair Goes
Recent studies link popular GLP-1 weight-loss drugs to unexpected dermatological side effects like nail detachment and hair loss.
◼ Archived
Health
Ozempic and Wegovy linked to rare risk of sudden vision loss
Recent coverage links GLP-1 medications like Ozempic and Wegovy to legal action involving vision loss alongside contrasting studies.
◼ Archived
Health
Man claims he went blind after taking Ozempic, shares warning for other users
A growing wave of coverage examines newly reported links between popular GLP-1 medications and rare instances of severe vision loss.
◼ Archived
Health
Two deaths were reported to the FDA. Is the bootleg weight-loss drug "Reta" to blame?
Federal regulators face mounting scrutiny as unapproved weight-loss drugs and new safety warnings enter public focus.
◼ Archived
Health
Popular weight loss drugs linked to a surprising fingernail problem
Popular weight loss medications face new scrutiny as coverage connects them to unusual nail and hair complications.
◼ Archived
Health
Austin father loses vision after taking Wegovy; questions raised about rare condition
7 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
◼ Archived
Health
Taking Ozempic or Wegovy? 2 New Studies Link GLP-1 Drugs to 2 Unexpected Problems
2 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
◼ Archived
Health
Nail detachment over four times more common among GLP-1 users, first controlled study finds
Recent studies link weight-loss medications like Ozempic and Wegovy to unexpected hair and nail side effects.
◼ Archived
Health
Does GLP-1 use result in significant hair loss?
7 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
People switching to Novo's Wegovy pill from obesity injections kept losing weight in real-world study
Real-world study data reveals patients switching from obesity injections to Novo Nordisk's oral Wegovy pill continue to lose weight.
◼ Archived
Health
Once described as obesity medicines for 'patients,' GLP-1s are increasingly lifestyle drugs for 'customers'
GLP-1 medications are shifting from clinical obesity treatments for patients to lifestyle products for customers, amid a surge in oral pill options.
◼ Archived
Business
Novo Nordisk to Pay Up to $1.3 Billion for Nanexa’s Drug Delivery Technology
Novo Nordisk strikes a $1.3 billion deal with Nanexa to secure long-acting obesity injection technology.
◼ Archived
Health
GLP-1 drugs fail to help some people lose weight
4 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
Hundreds of lawsuits allege GLP-1s like Ozempic, Wegovy, Mounjaro caused vision loss
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
Popular weight-loss drugs face numerous lawsuits over rare ‘eye stroke’ linked to vision loss
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Health
The dangerous risks of stopping Ozempic and GLP-1s
New reports warn that discontinuing GLP-1 weight-loss medications like Ozempic, Mounjaro, and Wegovy may increase the risk of heart attack and stroke.
◼ Archived
Business
GLP-1 makers Novo, Eli Lilly sued over sudden loss of vision in patients
Major drugmakers Novo Nordisk and Eli Lilly face numerous lawsuits alleging popular GLP-1 medications cause sudden vision loss.
◼ Archived
Business
What GLP-1 users should know about the potential risk of a rare type of vision loss
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
Wegovy maker Novo shares slump as management grilled on pricing, M&A
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
Wegovy Maker Novo Looks to New Drugs to Combat Lilly, but Investors Are Unconvinced
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
Wegovy-maker Novo faces calls to map out strategy beyond weight-loss drugs
Novo Nordisk shares slide despite aggressive obesity targets as investors demand a broader long-term strategy.
◼ Archived
Health
Novo Nordisk (NVO) and Eli Lilly (LLY)’s Weight-Loss Drugs Still Work at Smaller Doses, Study Finds
Recent studies indicate that popular weight-loss treatments manufactured by Novo Nordisk and Eli Lilly retain efficacy at reduced doses.
◼ Archived
Health
Large genetic study links GLP-1 receptor activation to improved mental well-being
A large genetic study connects GLP-1 receptor activation to improved mental well-being.
◼ Archived
Business
Will Wegovy Be A Part D, A Medicare GLP-1 Bridge Drug Or Neither?
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Health
🔮 fades ✗
Scientists Found a Surprising Effect of Ozempic. It Involves Your Lungs
New research indicates that GLP-1 medications like Ozempic and Wegovy may significantly reduce the frequency of asthma attacks and COPD flare-ups.
◼ Archived
Health
🔮 fades ✗
Weight regain after obesity drugs tied to higher odds of suicidal thoughts in observational study
A new observational study links weight regain following the use of obesity medications to an increased risk of suicidal thoughts.
◼ Archived
Business
🔮 fades ✓
Novo’s blockbuster hopes for CKD program dwindle after more phase 3 trials scrapped
Novo Nordisk faces a divergent clinical outlook as its pediatric obesity trials succeed while heart drug programs for CKD suffer setbacks.
◼ Archived
Business
🔮 fades ✗
Novo Nordisk Says Wegovy Shot Helped Children Lose Weight in Trial
Novo Nordisk's Wegovy shows weight-loss results in young children during trial data releases.
◼ Archived
Health
🔮 fades ✓
Scientists Flag Shocking New Concern for Men on GLP-1 Drugs
A new study suggests a genetic link between the use of GLP-1 weight-loss medications and increased hair loss risks for certain men.
◼ Archived
Health
🔮 holds ✓
GLP-1 medications may worsen or speed hair loss in some men, study finds
Recent studies indicate that GLP-1 weight loss medications may worsen or accelerate hair loss in men.
◼ Archived
Health
🔮 fades ✓
Don’t take GLP-1s? Be prepared to explain yourself.
A growing cultural and medical debate is emerging over the use of GLP-1 medications, focusing on the tension between clinical benefits and social stigma.
◼ Archived
Health
🔮 fades ✗
Experts call for safer weight loss as concerns grow over GLP-1 use - News-Medical
Experts call for safer weight loss methods as public and medical attention intensifies around the use and effectiveness of GLP-1 medications.
◼ Archived
Health
🔮 fades ✗
Wegovy and Zepbound are changing how Americans get health care
5 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
◼ Archived
Health
🔮 fades ✓
New Research Shows a Strong Link Between This GLP Medication and Hair Loss. Experts Weigh In.
3 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
◼ Archived
Health
🔮 fades ✗
GLP-1s May Be Working in an Entirely Different Way Than We Thought
New scientific discoveries regarding brain circuits may redefine the understood mechanism of GLP-1 weight loss drugs like Ozempic and Wegovy.
◼ Archived
Health
🔮 fades ✗
Unexpected brain mechanism challenges assumptions about GLP-1s
3 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
◼ Archived
Health
🔮 fades ✓
Nearly 200 deaths linked to weight-loss drugs Ozempic and Mounjaro in the UK
Regulators receive hundreds of reports linking popular weight-loss drugs to deaths.
◼ Archived
Business
🔮 fades ✓
Novo outlook hike falls flat as Wegovy pill sales fail to impress
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Health
🔮 fades ✓
As of July 1, Medicare Covers Wegovy for Weight Loss at $50 a Month. The Eligibility List Is Short.
4 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✓
Some people are getting shut out when it comes to GLP-1 drugs. Here’s why.
Patients are facing restricted access to GLP-1 drugs like Ozempic and Wegovy due to high costs and restrictive insurance policies.
◼ Archived
Health
🔮 fades ✓
Rare eye disorder linked to Ozempic-like medications
Australian regulators and medical reports link GLP-1 weight-loss drugs like Ozempic to a rare and severe risk of permanent vision loss.
◼ Archived
Health
🔮 holds
Georgia woman part of lawsuit claiming link between GLP-1 weight loss drugs and blindness - WSB-TV
A Georgia woman has joined a growing lawsuit connecting popular GLP-1 weight loss drugs to a rare and blinding eye condition.
◼ Archived
Health
🔮 fades
Does stopping a GLP-1 really doom you to regain all the weight?
Recent medical reviews suggest users of GLP-1 weight-loss medications may face significant weight regain after stopping treatment.
◼ Archived
Health
🔮 fades
She Used Weight-Loss Drugs From a Telehealth Company, Then a GLP-1 Overdose Sent Her to the ER
A 54-year-old woman's emergency room hospitalization after a GLP-1 overdose highlights rising public safety concerns.
◼ Archived
Business
🔮 fades
11% of Americans Are Currently Taking a GLP-1 Weight Loss Drug Like Wegovy
Recent data indicates that 11% of the American population is now utilizing GLP-1 weight loss medications such as Wegovy.
◼ Archived
Health
🔮 fades
Wegovy weight loss pill now available in UK
Wegovy weight‑loss pill hits UK shelves today, sparking a predicted rush of tens of thousands of users.
◼ Archived
Business
🔮 fades
Medicare is about to cover GLP-1 drugs for weight loss. Here’s what to know.
Medicare initiates a pilot program providing coverage for GLP-1 weight-loss medications beginning July 1, 2026.
◼ Archived
Health
🔮 fades
When Diets Don’t Work: Parents Turn to Wegovy for Elementary School Kids
Parents are increasingly administering weight-loss medications like Wegovy to elementary school children as young as six to combat obesity.